Contact Us: 01282 426380
KM Financial Solutions | China’s Henlius Biotech prices Hong Kong IPO at bottom end of range – sources
51560
post-template-default,single,single-post,postid-51560,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

China’s Henlius Biotech prices Hong Kong IPO at bottom end of range – sources

17 Sep China’s Henlius Biotech prices Hong Kong IPO at bottom end of range – sources

Posted at 09:23h in News by
0 Likes
Shanghai Henlius Biotech
has raised $410 million after pricing its Hong Kong
initial public offering at the bottom end of the indicative
pricing range, two people with direct knowledge of the matter
said on Wednesday.

No Comments

Sorry, the comment form is closed at this time.